Vaccination with the PD-L1–derived peptide is additionally being tested in several other ongoing trials, e.g., in combination with an IDO peptide and nivolumab in a phase I/II study in malignant melanoma (NCT03047928) and with an PD-L2 peptide in a phase I study in Follicular Lymphoma (NCT03381768). This evidence concerns the gene IDO1 and melanoma.